Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker

Orhan Aktas, Michael A Smith, William A Rees, Jeffrey L Bennett, Dewei She, Eliezer Katz, Bruce A C Cree, N-MOmentum scientific group and the N-MOmentum study investigators, Kazuo Fujihara, Friedemann Paul, Hans-Peter Hartung, Romain Marignier, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Gary R Cutter, Ari J Green, Maureen A Mealy, Jorn Drappa, Orhan Aktas, Michael A Smith, William A Rees, Jeffrey L Bennett, Dewei She, Eliezer Katz, Bruce A C Cree, N-MOmentum scientific group and the N-MOmentum study investigators, Kazuo Fujihara, Friedemann Paul, Hans-Peter Hartung, Romain Marignier, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Gary R Cutter, Ari J Green, Maureen A Mealy, Jorn Drappa

Abstract

Objective: Blood tests to monitor disease activity, attack severity, or treatment impact in neuromyelitis optica spectrum disorder (NMOSD) have not been developed. This study investigated the relationship between serum glial fibrillary acidic protein (sGFAP) concentration and NMOSD activity and assessed the impact of inebilizumab treatment.

Methods: N-MOmentum was a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial in adults with NMOSD. sGFAP levels were measured by single-molecule arrays (SIMOA) in 1,260 serial and attack-related samples from 215 N-MOmentum participants (92% aquaporin 4-immunoglobulin G-seropositive) and in control samples (from healthy donors and patients with relapsing-remitting multiple sclerosis).

Results: At baseline, 62 participants (29%) exhibited high sGFAP concentrations (≥170 pg/ml; ≥2 standard deviations above healthy donor mean concentration) and were more likely to experience an adjudicated attack than participants with lower baseline concentrations (hazard ratio [95% confidence interval], 3.09 [1.6-6.1], p = 0.001). Median (interquartile range [IQR]) concentrations increased within 1 week of an attack (baseline: 168.4, IQR = 128.9-449.7 pg/ml; attack: 2,160.1, IQR = 302.7-9,455.0 pg/ml, p = 0.0015) and correlated with attack severity (median fold change from baseline [FC], minor attacks: 1.06, IQR = 0.9-7.4; major attacks: 34.32, IQR = 8.7-107.5, p = 0.023). This attack-related increase in sGFAP occurred primarily in placebo-treated participants (FC: 20.2, IQR = 4.4-98.3, p = 0.001) and was not observed in inebilizumab-treated participants (FC: 1.1, IQR = 0.8-24.6, p > 0.05). Five participants (28%) with elevated baseline sGFAP reported neurological symptoms leading to nonadjudicated attack assessments.

Interpretation: Serum GFAP may serve as a biomarker of NMOSD activity, attack risk, and treatment effects. ANN NEUROL 2021;89:895-910.

Trial registration: ClinicalTrials.gov NCT02200770.

Conflict of interest statement

Viela Bio and MedImmune funded the N‐MOmentum study. Viela Bio is the owner of inebilizumab. Mitsubishi Tanabe Pharma Corporation and Hansoh Pharmaceutical Group Co. Ltd. have partnerships with Viela Bio to develop and commercialize inebilizumab for NMOSD (and other potential indications) in Asia. O.A. serves on a steering committee for Viela Bio and has received funding for travel and fees from Viela Bio. M.A.S., W.R., D.S., and E.K. are employees of Viela Bio. J.L.B. reports payment for study design/consultation from Viela Bio and personal fees from Mitsubishi Tanabe Pharma Corporation. B.A.C.C. has nothing to report.

© 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Figures

FIGURE 1
FIGURE 1
Baseline sGFAP concentration in the reference and NMOSD cohorts, and correlation of sGFAP with age. *p < 0.05; **p < 0.01; **p < 0.001. (A) Graph shows baseline sGFAP concentrations by cohort and antibody serostatus. Dashed line represents 2 SDs from the healthy donor mean (170 pg/ml). Box and whiskers represent sample quartiles. Statistical significance of differences in sGFAP concentration between groups was assessed using the Mann–Whitney U test. (B and C) Graphs show the correlation between age and baseline sGFAP concentration in both heathy donors and NMOSD participants. AQP4+ = aquaporin 4‐immunoglobulin G seropositive; DN = double negative serostatus; MOG+ = myelin oligodendrocyte glycoprotein‐immunoglobulin G seropositive; NMOSD = neuromyelitis optica spectrum disorder; RRMS = relapsing–remitting multiple sclerosis; SD = standard deviation; sGFAP = serum glial fibrillary acidic protein.
FIGURE 2
FIGURE 2
Attack‐free survival in participants with NMOSD according to treatment and baseline sGFAP status. Graphs show Kaplan–Meier plots of time until first NMOSD attack during the RCP in (A) placebo and (B) inebilizumab participants with baseline sGFAP concentration ≥170 pg/ml versus those with baseline sGFAP concentration

FIGURE 3

The sGFAP concentration at baseline…

FIGURE 3

The sGFAP concentration at baseline at visits leading to an adjudicated NMOSD attack,…

FIGURE 3
The sGFAP concentration at baseline at visits leading to an adjudicated NMOSD attack, and during attack. (A) Graph shows a boxplot of sGFAP measurements leading up to attack in 38 participants who experienced an adjudicated attack and provided sGFAP measurements. Baseline samples >5 weeks from attack were available in 30 of 38 participants. Eight participants experienced attacks within 5 weeks of the baseline sample collection. (B) Graph shows a profile plot of sGFAP measurements in the days leading up to the attack. Graphs show sGFAP concentration of samples drawn most proximal to attack and within 1 week of adjudicated NMOSD attack by attack severity (C) and organ domain involvement (D), measured by the OSIS. Of the attacks across multiple domains, 4 were minor myelitis attacks, and one sample from myelitis major group displayed sGFAP within the healthy donor range. Box and whiskers represent sample quartiles. Statistical significance between groups was assessed using Mann–Whitney U test. Dashed lines represent 2 SDs from the healthy donor mean (170 pg/ml). NMOSD = neuromyelitis optica spectrum disorder; ON = optic neuritis; OSIS = Opticospinal Impairment Scale; RCP = randomized controlled period; SD = standard deviation; sGFAP = serum glial fibrillary acidic protein.

FIGURE 4

The sGFAP concentration during adjudicated…

FIGURE 4

The sGFAP concentration during adjudicated NMOSD attacks. (A and B) Graphs show sGFAP…

FIGURE 4
The sGFAP concentration during adjudicated NMOSD attacks. (A and B) Graphs show sGFAP concentration of most proximal samples drawn within 1 week of attack according to treatment in participants with attacks. Statistical significance of increases from baseline was assessed using the Wilcoxon signed‐rank test. Dashed line represents sGFAP concentration 2 SDs from the healthy donor mean (170 pg/ml). (C) Graph displays time course of FC in sGFAP from baseline in the weeks leading up to and proceeding adjudicated attacks. Points represent medians, error bars represent IQR. (D) The sGFAP concentration during adjudicated NMOSD attacks according to treatment group and antibody serostatus. Box and whiskers represent sample quartiles. DN = double negative serostatus; FC = fold change; IQR = interquartile range; MOG+ = myelin oligodendrocyte glycoprotein‐immunoglobulin G seropositive; RCP = randomized controlled period; SD = standard deviation; sGFAP = serum glial fibrillary acidic protein.

FIGURE 5

Change in sGFAP concentration from…

FIGURE 5

Change in sGFAP concentration from baseline in participants who did not experience an…

FIGURE 5
Change in sGFAP concentration from baseline in participants who did not experience an adjudicated NMOSD attack. (A) Graph shows change in sGFAP concentration over time in participants without attacks. Error bars represent interquartile range. Statistical significance of percentage change from baseline, comparing inebilizumab to placebo, was assessed using the Mann–Whitney U test; *p < 0.05; **p < 0.01; ***p < 0.001; week 16 changes from baseline remained significant (adjusted p value < 0.05) between dose groups after the Bonferroni correction was applied to p values. Nineteen of 117 (16%) inebilizumab samples and 9/26 (35%) placebo samples were outside healthy donor range (Fisher's exact test, p = 0.052). (B) Graph shows proportion of participants with elevated sGFAP concentrations (≥170 pg/ml) at week 28 of the RCP in participants receiving placebo or inebilizumab. FC = fold change; NMOSD = neuromyelitis optica spectrum disorder; RCP = randomized controlled period; sGFAP = serum glial fibrillary acidic protein.

FIGURE 6

The sGFAP increases in participants…

FIGURE 6

The sGFAP increases in participants without adjudicated attacks are correlated with disease activity.…

FIGURE 6
The sGFAP increases in participants without adjudicated attacks are correlated with disease activity. (A) Profile plot of longitudinal fold change from baseline in sGFAP concentration in participants with NMOSD who experienced adjudicated attacks (gold), those who did not experience adjudicated attacks but displayed an increase greater than twofold from baseline (blue), and in those who neither experienced attacks nor displayed increases greater than twofold from baseline (gray) in sGFAP during the RCP. (B) Boxplots displaying sGFAP concentrations observed in 10 healthy controls across 3 blood draws. Proportion of (C) new spinal cord T2 or (D) Gd‐enhancing T1 lesions observed in participants who did not experience committee‐adjudicated attacks and had MRI scans, but either did or did not display a greater than twofold increase in sGFAP during the RCP. (E) Bar chart shows proportion of participants with an increase greater than twofold in sGFAP from baseline. The total number of participants at each time point represent those remaining in the RCP with available sGFAP data. Statistical significance in the between‐group difference was assessed using the Cochran–Armitage test, *p < 0.05; **p < 0.01; ***p < 0.001, week 16 changes from baseline remained significant (adjusted p value < 0.05) after the Bonferroni correction was applied to p values. AC = adjudication committee; CI = confidence interval; FC = fold change; Gd = gadolinium; MRI = magnetic resonance imaging; NMOSD = neuromyelitis optica spectrum disorder; OR = odds ratio; RCP = randomized controlled period; sGFAP = serum glial fibrillary acidic protein.
FIGURE 3
FIGURE 3
The sGFAP concentration at baseline at visits leading to an adjudicated NMOSD attack, and during attack. (A) Graph shows a boxplot of sGFAP measurements leading up to attack in 38 participants who experienced an adjudicated attack and provided sGFAP measurements. Baseline samples >5 weeks from attack were available in 30 of 38 participants. Eight participants experienced attacks within 5 weeks of the baseline sample collection. (B) Graph shows a profile plot of sGFAP measurements in the days leading up to the attack. Graphs show sGFAP concentration of samples drawn most proximal to attack and within 1 week of adjudicated NMOSD attack by attack severity (C) and organ domain involvement (D), measured by the OSIS. Of the attacks across multiple domains, 4 were minor myelitis attacks, and one sample from myelitis major group displayed sGFAP within the healthy donor range. Box and whiskers represent sample quartiles. Statistical significance between groups was assessed using Mann–Whitney U test. Dashed lines represent 2 SDs from the healthy donor mean (170 pg/ml). NMOSD = neuromyelitis optica spectrum disorder; ON = optic neuritis; OSIS = Opticospinal Impairment Scale; RCP = randomized controlled period; SD = standard deviation; sGFAP = serum glial fibrillary acidic protein.
FIGURE 4
FIGURE 4
The sGFAP concentration during adjudicated NMOSD attacks. (A and B) Graphs show sGFAP concentration of most proximal samples drawn within 1 week of attack according to treatment in participants with attacks. Statistical significance of increases from baseline was assessed using the Wilcoxon signed‐rank test. Dashed line represents sGFAP concentration 2 SDs from the healthy donor mean (170 pg/ml). (C) Graph displays time course of FC in sGFAP from baseline in the weeks leading up to and proceeding adjudicated attacks. Points represent medians, error bars represent IQR. (D) The sGFAP concentration during adjudicated NMOSD attacks according to treatment group and antibody serostatus. Box and whiskers represent sample quartiles. DN = double negative serostatus; FC = fold change; IQR = interquartile range; MOG+ = myelin oligodendrocyte glycoprotein‐immunoglobulin G seropositive; RCP = randomized controlled period; SD = standard deviation; sGFAP = serum glial fibrillary acidic protein.
FIGURE 5
FIGURE 5
Change in sGFAP concentration from baseline in participants who did not experience an adjudicated NMOSD attack. (A) Graph shows change in sGFAP concentration over time in participants without attacks. Error bars represent interquartile range. Statistical significance of percentage change from baseline, comparing inebilizumab to placebo, was assessed using the Mann–Whitney U test; *p < 0.05; **p < 0.01; ***p < 0.001; week 16 changes from baseline remained significant (adjusted p value < 0.05) between dose groups after the Bonferroni correction was applied to p values. Nineteen of 117 (16%) inebilizumab samples and 9/26 (35%) placebo samples were outside healthy donor range (Fisher's exact test, p = 0.052). (B) Graph shows proportion of participants with elevated sGFAP concentrations (≥170 pg/ml) at week 28 of the RCP in participants receiving placebo or inebilizumab. FC = fold change; NMOSD = neuromyelitis optica spectrum disorder; RCP = randomized controlled period; sGFAP = serum glial fibrillary acidic protein.
FIGURE 6
FIGURE 6
The sGFAP increases in participants without adjudicated attacks are correlated with disease activity. (A) Profile plot of longitudinal fold change from baseline in sGFAP concentration in participants with NMOSD who experienced adjudicated attacks (gold), those who did not experience adjudicated attacks but displayed an increase greater than twofold from baseline (blue), and in those who neither experienced attacks nor displayed increases greater than twofold from baseline (gray) in sGFAP during the RCP. (B) Boxplots displaying sGFAP concentrations observed in 10 healthy controls across 3 blood draws. Proportion of (C) new spinal cord T2 or (D) Gd‐enhancing T1 lesions observed in participants who did not experience committee‐adjudicated attacks and had MRI scans, but either did or did not display a greater than twofold increase in sGFAP during the RCP. (E) Bar chart shows proportion of participants with an increase greater than twofold in sGFAP from baseline. The total number of participants at each time point represent those remaining in the RCP with available sGFAP data. Statistical significance in the between‐group difference was assessed using the Cochran–Armitage test, *p < 0.05; **p < 0.01; ***p < 0.001, week 16 changes from baseline remained significant (adjusted p value < 0.05) after the Bonferroni correction was applied to p values. AC = adjudication committee; CI = confidence interval; FC = fold change; Gd = gadolinium; MRI = magnetic resonance imaging; NMOSD = neuromyelitis optica spectrum disorder; OR = odds ratio; RCP = randomized controlled period; sGFAP = serum glial fibrillary acidic protein.

References

    1. Cree BA, Bennett JL, Sheehan M, et al. Placebo‐controlled study in neuromyelitis optica‐ethical and design considerations. Mult Scler 2016;22:862–872.
    1. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1–16.
    1. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270–1272.
    1. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta‐analysis. JAMA Neurol 2016;73:1342–1348.
    1. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN‐1 study): a multicentre, randomised, double‐blind, placebo‐controlled trial. Lancet Neurol 2020;19:298–306.
    1. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin‐4‐positive neuromyelitis optica spectrum disorder. N Engl J Med 2019;381:614–625.
    1. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019;381:2114–2124.
    1. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N‐MOmentum): a double‐blind, randomised placebo‐controlled phase 2/3 trial. Lancet 2019;394:1352–1363.
    1. Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 2019;32:385–394.
    1. Chen D, Gallagher S, Monson NL, et al. Inebilizumab, a B cell‐depleting anti‐CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies. J Clin Med 2016;5:107.
    1. Schiopu E, Chatterjee S, Hsu V, et al. Safety and tolerability of an anti‐CD19 monoclonal antibody, MEDI‐551, in subjects with systemic sclerosis: a phase I, randomized, placebo‐controlled, escalating single‐dose study. Arthritis Res Ther 2016;18:131.
    1. Agius MA, Klodowska‐Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI‐551), an anti‐CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo‐controlled, escalating intravenous and subcutaneous dose study. Mult Scler 2019;25:235–245.
    1. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic‐spinal multiple sclerosis binds to the aquaporin‐4 water channel. J Exp Med 2005;202:473–477.
    1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106–2112.
    1. Zekeridou A, Lennon VA. Aquaporin‐4 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2015;2:e110.
    1. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630–643.
    1. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti‐aquaporin‐4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66:617–629.
    1. Liem RK, Messing A. Dysfunctions of neuronal and glial intermediate filaments in disease. J Clin Invest 2009;119:1814–1824.
    1. Papa L, Lewis LM, Falk JL, et al. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 2012;59:471–483.
    1. Petzold A. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res 2015;1600:17–31.
    1. Brenner M, Johnson AB, Boespflug‐Tanguy O, et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 2001;27:117–120.
    1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107–1114.
    1. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4‐IgG‐positive relapsing neuromyelitis optica spectrum disorders: an open‐label pilot study. Lancet Neurol 2013;12:554–562.
    1. Abdelhak A, Huss A, Kassubek J, et al. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep 2018;8:14798.
    1. Czeiter E, Amrein K, Gravesteijn BY, et al. Blood biomarkers on admission in acute traumatic brain injury: relations to severity, CT findings and care path in the CENTER‐TBI study. EBioMedicine 2020;56:102785.
    1. Marshall WJ, Bangert SK. Clinical biochemistry: metabolic and clinical aspects. 2nd ed. London, UK: Churchill Livingstone, 2008.
    1. Lucchinetti CF, Guo Y, Popescu BF, et al. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 2014;24:83–97.
    1. Kuhle J, Kropshofer H, Meinert R, et al. Plasma glial fibrillary acidic protein correlates with characteristics of advanced disease and treatment response in secondary progressive multiple sclerosis. Paper presented at: 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 11–13 September 2019, Stockholm, Sweden (Abstract P1630).
    1. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010;119:7–35.
    1. Petzold A, Marignier R, Verbeek MM, Confavreux C. Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases. J Neurol Neurosurg Psychiatry 2011;82:467–469.
    1. Misu T, Takano R, Fujihara K, et al. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009;80:575–577.
    1. Takano R, Misu T, Takahashi T, et al. A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med 2008;215:55–59.
    1. Uzawa A, Mori M, Sawai S, et al. Cerebrospinal fluid interleukin‐6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 2013;421:181–183.
    1. Rissin DM, Kan CW, Campbell TG, et al. Single‐molecule enzyme‐linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595–599.
    1. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577–589.
    1. Hogel H, Rissanen E, Barro C, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler 2018;26:210–219.
    1. Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 2019;93:e1299–e1311.
    1. Jeong IH, Choi JY, Kim SH, et al. Normal‐appearing white matter demyelination in neuromyelitis optica spectrum disorder. Eur J Neurol 2017;24:652–658.
    1. Ventura RE, Kister I, Chung S, et al. Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI‐visible lesions. Neurol Neuroimmunol Neuroinflamm. 2016;3:e224.
    1. Jeong IH, Kim HJ, Kim NH, et al. Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder. J Neurol 2016;263:1343–1348.
    1. Oertel FC, Havla J, Roca‐Fernandez A, et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry 2018;89:1259–1265.
    1. Oertel FC, Kuchling J, Zimmermann H, et al. Microstructural visual system changes in AQP4‐antibody‐seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm 2017;4:e334.
    1. Ringelstein M, Kleiter I, Ayzenberg I, et al. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler 2014;20:617–620.
    1. Ringelstein M, Harmel J, Zimmermann H, et al. Longitudinal optic neuritis‐unrelated visual evoked potential changes in NMO spectrum disorders. Neurology 2020;94:e407–e418.
    1. Mestre H, Mori Y, Nedergaard M. The brain's glymphatic system: current controversies. Trends Neurosci 2020;43:458–466.
    1. Da Mesquita S, Fu Z, Kipnis J. The meningeal lymphatic system: a new player in neurophysiology. Neuron 2018;100:375–388.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa